BOSENTAN VS PLACEBO IN NYHA CLASS I/II SCLERODERMA PATIENTS WITH EXERCISE INDUCE

波生坦与安慰剂在 NYHA I/II 级硬皮病患者运动诱导中的比较

• 批准号: 7719053
• 负责人: VIRGINIA D STEEN
• 金额: $ 0.43万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719053
• 关键词: Class; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Double-Blind Method; Exercise; Funding; Grant; Institution; Lung; Patients; Placebos; Pulmonary Hypertension; Research; Research Personnel; Resources; Risk; Scleroderma; Source; United States National Institutes of Health; bosentan; pressure

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Scleroderma patients have a high risk for developing pulmonary hypertension (PAH). We know that some of the abnormalities found in PAH occur many years prior to the definite diagnosis of PAH. Exercise induced PAH occurs in idiopathic PAH, and we have found that 47% of scleroderma patients without definite PAH have increases in the pulmonary pressures. This study is a double blind controlled trial of bosentan, one of the approved treatments for PAH, vs placebo in a 4 month study. It will determine whether any of the more subtle findings of early PAH respond to bosentan.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 硬皮病患者患肺动脉高压（PAH）的风险很高。 我们知道，在PAH明确诊断PAH之前，PAH中发现的一些异常发生。 运动引起的PAH发生在特发性PAH中，我们发现47％的没有明确PAH的硬皮病患者的肺部压力增加。 这项研究是波森坦的双盲对照试验，波森坦是PAH的认可治疗方法之一，在4个月的研究中与安慰剂相比。 它将决定早期PAH的任何更微妙的发现是否对波森坦作出反应。